PubMed Health⌕ Search

Biomedical subjects

M H Becquemin

Publications and source records attributed to M H Becquemin.

At least 19 recordsLinked to original sources
PubMed2001

Validation of laser diffraction method as a substitute for cascade impaction in the European Project for a Nebulizer Standard.

The project for a European standard testing procedure to characterize nebulizers in terms of particle size distribution has been based on using the Andersen-Marple personal cascade impactor model 298 (A-MPCI) with a sodium fluoride reference solution. In the present study methods based on laser diffraction (Mastersizer-X) and time-of-flight (TOF)(APS) and another cascade impactor (GS1-CI) were compared with the A-MPCI. Two types of nebulizer (Pari LC+ and Microneb) were tested with all apparatuses, and a third type of nebulizer (NL9) was tested with the A-MPCI and Mastersizer-X. Nebulizers were charged with a solution of sodium fluoride in conditions reproducing the European Committee for Normalization (CEN) protocol. There was no difference between the Mastersizer-X and the A-MPCI or between the GS1-CI and the A-MPCI in terms of mass median aerodynamic diameter (MMAD). Comparison between the APS and the A-MPCI showed a significant difference with the Microneb. The geometric standard deviations (GSD) obtained with the A-MPCI were on average 10% greater than GSD obtained with the other apparatuses, but the differences were not statistically significant. We conclude that laser diffraction can be used for particle size distribution in the context of the European standard, and that the Mastersizer-X is particularly interesting for industrial practice in view of its simplicity and robustness.

Equipment Design↗
PubMed2001

[Optimization of aerosol therapy in otorhinolaryngology: stability and granulometry of dexamethasone-gomenol-framycetin solution].

Nebulization of solutions associating gomenol, dexamethasone and framycetin is very widespread in otorhinolaryngology (particularly for the treatment of actue laryngitis and post-traumatic laryngitis and rhinitis and for the tracheotomy care). A rigorous clinical evaluation is however lacking. The aim of this work was to evaluate use of such solutions in comparison with the recommendations issuing from the National Session in April 1997 on good practices for aerosol therapeutics. Stability and granulometry were studied in order to optimize processing. A new formulation and new technical methods of administration are proposed in relation to the results of this study and the national recommendations.

Aerosols↗
PubMed1999

Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease.

In 18 patients with chronic obstructive pulmonary disease intubated and mechanically ventilated, we prospectively randomized 200 micrograms fenoterol-80 micrograms ipratropium bromide (four puffs) from a metered-dose inhaler (MDI) versus 1.25 mg fenoterol-500 micrograms ipratropium bromide in 5 ml saline from a nebulizer (NEB). Respiratory mechanics were assessed before and 30 min after the end of each delivery by the rapid end-inspiratory airway occlusion technique. We did vary on single breaths the inflation flow (V) from 0.2 to 1.2 L. s-1, at constant inflation volume. The total respiratory resistance of the respiratory system (Rrs) was partitioned into airway (Rint,rs) and tissue (DeltaRrs) resistances. We found that Rrs was equivalently reduced, from 16.49 +/- 1.37 to 14.85 +/- 1.88 cm H2O. L-1. s with MDI (p < 0.05) and from 18.04 +/- 1.85 to 15.15 +/- 1.33 cm H2O. L-1. s with NEB (p < 0.01). Whereas the prevailing effect of MDI was to reduce Rint,rs, that of NEB was to decrease DeltaRrs. In addition, the V resistance of the respiratory system over the whole range of V was significantly affected by NEB but not by MDI.

Administration, Inhalation↗
PubMed1998

Experimental measurements of particle retention efficiency of filters used to prevent contamination in respiratory devices.

OBJECTIVE: Various types of filters have been designed to prevent cross contamination of ventilation and respiratory devices. The aim of this study was to experimentally measure the retention efficiency of four simple filters (antibacterial and antiviral and seven combined filters (antibacterial and antiviral plus heat and water exchangers). SETTING: The respiratory function testing (EFR) central department of a university teaching hospital. MEASUREMENTS AND RESULTS: The same aerosol test with a wide range of particle sizes (0.15 to 15 micrometers) was used to compare the retention efficiency of each filter used in various conditions. The particle sizes and the concentration of the aerosol were measured by a laser velocimeter. For all the filters studied, the retention efficiency was found to be higher than 99%. However some of them let large particles let through. CONCLUSION: These data, performed in vitro, should be assessed also by further clinical studies.

Air Pollutants↗
PubMed1995

Comparison of jet and ultrasonic nebulizers for alveolar targeting of methylprednisolone.

The secondary systemic effects of oral corticosteroid therapy in chronic lung disease indicate the possible benefits of local therapy. The aim of this study was to show if alveolar targeting of a corticosteroid, methylprednisolone (MP), is possible, and to determine which type of nebulizer allows the most selective deposition into the alveoli. A jet nebulizer (Respirgard II) with 2 ml volume fill (R2), and an ultrasonic nebulizer (Ultraneb 99) with 4 ml volume fill (U4), were compared using a 40-mg dose of MP labelled 99Tcm human serum albumin. Particle size and MP-to-albumin binding were measured in the aerosol cloud. Each nebulizer was used in random order in five healthy volunteers. A dynamic posterior scan of 68 images of 15 s each was performed with a Gammatome II gamma camera during inhalation. Peripheral and central regions of interest were automatically defined with reproducible methods, and the peripheral-to-central ratio was used as a penetration index. Stomach and oropharynx activities were estimated on static anterior and static left lateral views, respectively, at the end of the examination. The mass median aerodynamic diameter (MMAD) was lower for R2 when unlabelled MP was used. The MMAD of MP+HSA was compatible with alveolar targeting. In the aerosol cloud, MP-albumin binding was 75% for R2 and 79% for U4. Peripheral and central activities at equilibrium (13-16 min) were higher with U4, but the penetration index was significantly higher with R2. Moreover, the stomach and oropharynx activities were significantly lower with R2.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1994

Pulmonary deposition of aerosolised pentamidine using a new nebuliser: efficiency measurements in vitro and in vivo.

The therapeutic efficacy of nebulised pentamidine in the prophylaxis of Pneumocystis carinii pneumonia (PCP) depends on the absolute pulmonary deposition of the drug. We studied the performance of a new nebuliser (Pentasave) by comparison both in vitro and in vivo with a standard nebuliser (Respirgard II). In vitro, deposition of pentamidine labelled with technetium-99m human serum albumin was measured indirectly by capturing inhaled particles on an absolute filter and measuring radioactivity with a gamma camera. The nebulisers were initially assessed with a pentamidine dose of 100 mg in 5 ml at 44 psi and an air flow of 10 l/min for Respirgard II and 16 l/min for Pentasave. Nebuliser output, expressed as the percentage of the initial nebuliser radioactivity captured by the inhalation filter, was 15% +/- 2% (mean +/- SD) for Respirgard II, and significantly increased to 23% +/- 3% for an initial version and to 33% +/- 2% for the final version of Pentasave. Measurements with a gamma camera in a group of ten patients with human immunodeficiency virus infection were made in vivo. The results revealed that pulmonary drug distributions are good using both Respirgard II and Pentasave. The literature reports that once-monthly pulmonary deposition of 9 mg pentamidine seems enough to produce prophylactic effects against Pneumocystis carinii. We measured pulmonary pentamidine deposition of 20.22 +/- 4.31 mg (mean +/- SD) using Respirgard II (with 300 mg in 5 ml) and of 16.00 +/- 7.18 mg using Pentasave (with 150 mg in 6 ml). These findings show that the therapeutic dose of pentamidine (9 mg) was widely exceeded with both nebulisers. Further investigations might demonstrate that about 200 mg and 125 mg pentamidine for Respirgard II and Pentasave, respectively, will achieve a pulmonary deposition of therapeutic dose, allowing significant savings in terms of drug and expense.

Administration, Inhalation↗
PubMed1994

[Granulometry and measurement of a aerosol drug deposit (fusafungine) in normal and pathological airways].

We measured with a laser velocimeter granulometric deposit of an aerosol anti-infectious agent, fusafungin, administered with a controlled inhalator. Total drug deposit was determined on the basis of a granulometric spectrum of the polydispered aerosol (mass mean aerodynamic diameter (MMAD) = 2.8 +/- 1.7 microns) and dispersion in the airways was estimated using the Stahlhofen model. We first compared deposits obtained with oral inhalation in 19 normal subjects and 20 patients with chronic obstructive lung disease. Total deposit in the airways of patients with chronic obstructive lung disease (82%) was not significantly different from that in normal subjects (85%). Estimated dispersion in normal airways was 27% in the alveoles, 8.4% in the tracheobronchic region and 23.5% in the extrathoracic regions. We then compared deposits after nasal inhalation in 22 normal subjects and 21 patients with rhinitis: nasal deposit was significantly greater in patients with rhinitis (54.5%) than in controls (44.7%). We conclude that such an inhalator can be adapted for local treatment of ENT infections and upper respiratory infections. Deposit is not modified in case of obstructive bronchopathy.

Adult↗
PubMed1991

Particle deposition and resistance in the noses of adults and children.

Nasal filter efficiency for particles has been described by several authors as showing large individual variations, probably somehow related to airflow resistance. Twelve children, aged 5.5-11.5 yrs and 8 aged 12-15 yrs were compared to a group of ten adults. Deposition of polystyrene beads (1, 2.05, 2.8 microns mass median aerodynamic diameter (MMAD] was measured by comparing inhaled aerosols and exhaled air concentrations, for both nose and mouth breathing. Ventilation was controlled to scale breathing patterns appropriate for each age either at rest or during moderate exercise to allow comparison between subjects in similar physiological conditions. Anterior nasal resistance (as a function of flow rate) and standard lung function were measured for each subject. For the same inhalation flow rate of 0.300 l.s-1, children had much higher nasal resistances than the adults, 0.425 +/- 0.208 kPa.l.1.s under 12 yrs, 0.243 +/- 0.080 kPa.l.1.s over 12 yrs and 0.145 +/- 0.047 kPa.l.1.s in adults. Individually, nasal deposition increased with particle size, ventilation flow rate and nasal resistance, from rest to exercise. The average nasal deposition percentages were lower in children than in adults, in similar conditions: at rest, 12.9 and 11.7 versus 15.6 for 1 microns; 13.3 and 15.9 versus 21.6 for 2.05 microns; 11 and 17.7 versus 20 for 2.8 microns. This was even more significant during exercise, 17.8 and 15.9 versus 29.2 for 1 microns; 21.3 and 18.4 versus 34.7 for 2.05 microns; 16 and 16.1 versus 36.8 for 2.8 microns.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1991

[Which compressor should be used to deliver pentamidine aerosols with the Respirgard II?].

Prophylaxis against pneumonia due to Pneumocystis carinii is most often carried out using pentamidine administered as an aerosol. For reasons both of comfort and cost this technique should be developed at home or at least in an extra-hospital environment. Using the Respirgard II as the nebuliser of reference this requires a compressor. We have assessed four different compressors and compared these to pressurised oxygen used in a hospital environment. During the course of nebulisation with a pentamidine aerosol two physical factors may coincide to limit their efficacy. First the deposition of some of the particles on the walls of the apparatus and secondly the production of a particle size which is incompatible with alveolar deposition. This study showed that according to the source of compressed air: 1) the fraction of the pentamidine solution found in an aerosol at the mouthpiece varies from 29 to 62%; 2) the fraction of the aerosol whose particle size is suitable for alveolar deposition (1 to 3 microns) varies from 35 to 48%. The product of these two fractions enables an assessment of the efficiency of each apparatus: 14 to 24% of the pentamidine solution may be deposited at the alveolar level. In addition to this efficiency the duration of the session (from 25 to 50 minutes) for each machine should be taken into consideration when considering the choice of the compressor to be coupled with the Respirgard II in order to improve the comfort and therefore the compliance to the treatment.

Aerosols↗
PubMed1988

Particle size study of nine metered dose inhalers, and their deposition probabilities in the airways.

This study deals with the particle size measurement of nine aerosol metered dose inhalers. Calibration was made possible by the use of a laser particle velocimeter (aerodynamic Particle Sizer from TSI). The count median aerodynamic diameters (CMAD) show little variation, from 0.63 to 0.73 micron, with standard deviations (sigma g) between 1.2 and 1.8. Aerodynamic diameter aerosol diagram analysis showed multimodal mass distribution for all the tested dose inhalers. Calculations for the airway deposition probabilities (extrathoracic, tracheobronchial and alveolar) refer to the studies made by W. Stahlhofen and co-workers. As most aerosol metered dose inhalers have a predominantly bronchial therapeutic destination, the deposition at the bronchial level could be enhanced with the following parameters: inspired volume of 1500 ml, inspiratory time of 2 sec, aerosol mass median aerodynamic diameter (MMAD) of 7.5 microns, with a monodispersed distribution. The respective influences of the excipients and propellents used for the aerosolization of these dose metered inhalers are also discussed.

Aerosol Propellants↗
PubMed1987

Inhaled particle deposition and clearance from the normal respiratory tract.

Tracheo-bronchial and pulmonary deposited fractions of inhaled insoluble particles and their clearances rates were studied in 16 healthy non-smokers. After oral inhalation of radioactive particles (Mean Mass Aerodynamic Diameter (MMAD) = 3 microns, sigma g = 1.4 labelled with 111In) incorporated radioactivity was measured for each subject both by a gamma camera from to until the 3rd day, then from the 3rd until the 5th day first by a gamma camera and then by a low background profile scanner and from the 5th until the 35th day by a low background profile scanner alone. Clearance rates were calculated from the biological half lives of the deposited tracers. All subjects performed respiratory function tests. Experimental data were fitted to a two-compartment exponential system with two biological half lives: T1 = 76 min for 30%, T2 = 3.15 days for 40% of the deposited material. The delayed clearance phase for the remaining 30% of the deposited material approaches a constant rate. Our clearance values were compared with those of the Task Group of Lung Dynamics (T.G.L.D.) and other authors' results, especially for T1 and T2. These values are analyzed in terms of mucus velocity and mucociliary transport in distal conductive airways. Impaired transport reduces natural defenses and increases toxicological hazards. Therefore reliable techniques for detecting such impairment may be important in evaluating pulmonary involvement in environmental respiratory disease.

Adult↗
PubMed1985

Pulmonary function after transverse or midline incision in patients with obstructive pulmonary disease.

Atelectasis and bronchopneumonia occur frequently in patients undergoing aorto-iliac reconstructive surgery. Transverse (T) incisions in upper abdominal surgery are thought to be followed by fewer pulmonary complications than midline incisions (M) but reports remain controversial. We studied the incidence of postoperative pulmonary complications and lung dysfunction after T and M incisions for aorto-iliac surgery in 13 patients with chronic obstructive pulmonary disease (COPD) and 13 control patients with normal lungs (C). For all subjects, we evaluated (1) postoperative clinical or radiological pulmonary events; (2) preoperatively and on postoperative days 2 (D2), 5 (D5), 9 (D9) and 12 (D12) - the forced expiratory volume in 1 s (FEV1), vital capacity (VC), alveolar-arterial oxygen difference (AaPO2), and (3) convenience for the surgeon. Operatively, aortic exposure was excellent with both incisions. Bronchopneumonia occurred only after M in five patients (1 C, 4 COPD). In contrast with the control patients in whom no difference was found between T and M incisions, the FEV1 of COPD patients was significantly less impaired with T than with M incisions (p less than 0.005 on D2 and p less than 0.05 on D5). VC decreased similarly with both incisions on D2 but on D5 the improvement was less with M (p less than 0.005). Changes in AaPO2 were more marked on D2 and D5 for the COPD patients with M incisions. We conclude that (1) in patients with chronic obstructive pulmonary disease, laparotomy with a transverse incision was associated with better postoperative lung function and fewer pulmonary complications; (2) in patients without pulmonary disease, midline and transverse incisions were equivalent.

Abdominal Muscles↗
PubMedDate not supplied

[Short-term tracheobronchial clearance in apparently pure Gougerot-Sjögren syndrome].

Bronchopulmonary involvement in the Sjögren syndrome can lead to distal obstructive airway disease. This syndrome induces a decrease in secretions which become rare and thick, and consequently a slowing down of mucociliary activity. This activity, which can be estimated by tracheobronchial clearance studies, was investigated in seven non-smoking women (mean age = 56.7 yr) with the Sjögren syndrome but without patent distal bronchial impairment. After oral inhalation of radioactive particles labelled with 111In during spontaneous breathing (MMAD = 3 micrograms; sigma g = 1.4; energies gamma 173 and 247 keV, radioactive half-life = 2.8 days), the incorporated radioactivity was measured by a gamma-camera at the end of inhalation and then every 5 min throughout 90 min and 2, 4, 5, 6 and 24h thereafter. Biological decrease in radioactivity was exponential in form. Considering, as may authors do, the clearance of the tracheobronchial compartment to be completed within 24h, we calculated an initial biological period corresponding to the beginning of this clearance. It was equal to 101 +/- 27 min in 12 normal subjects. It was normal in three of our patients (T = 90, 91 and 101 min) and longer for the four others (T = 178, 203, 240 and 304 min). We hypothesize that three of these four patients with slow clearance and normal penetration index (tracheobronchial deposition/pulmonary deposition) had bronchiolar involvement, creating anomalies in the mucociliary escalator which were undetectable by clinical, radiological or functional examinations. These results argue in favour of strict pulmonary surveillance in patients with altered short-term clearances to enable early detection of bronchiolar disease.

Adult↗